EDAP News & Events

EDAP TMS announced that it will operate under the new corporate name FocalTherics to reflect its exclusive focus on high-growth robotic focal therapy. The company also announced its intention to report and classify its Extracorporeal Shock Wave Lithotripsy and Distribution operating segments as discontinued operations in the company's financial statements beginning with second quarter financial results. In conjunction with this defined focus, the company is changing its ticker symbol on Nasdaq from (EDAP) to (FOCL), effective at market open on June 1.

Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with EDAP TMS (EDAP) and Profound Medical (PROF), companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix's commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making. The collaborations will explore the investigational use of Telix's PSMA-PET1 imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound, or HIFU, and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation, or TULSA. Telix's intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement.